Minerva Neurosciences Inc. (NASDAQ:NERV) shares fell 2.4% on Wednesday . The stock traded as low as $12.37 and last traded at $12.62, with a volume of 345,269 shares traded. The stock had previously closed at $12.93.

Several brokerages recently weighed in on NERV. Zacks Investment Research downgraded Minerva Neurosciences from a “buy” rating to a “sell” rating in a research note on Wednesday, June 1st. Jefferies Group restated a “buy” rating and set a $17.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, June 8th. Finally, JMP Securities boosted their target price on Minerva Neurosciences from $10.00 to $17.00 in a research note on Thursday, May 26th.

The company has a 50 day moving average price of $11.02 and a 200 day moving average price of $7.91. The stock’s market capitalization is $441.33 million.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. During the same period last year, the firm earned ($0.27) EPS. Equities analysts forecast that Minerva Neurosciences Inc. will post ($0.90) earnings per share for the current year.

In related news, Director David Kupfer acquired 55,635 shares of Minerva Neurosciences stock in a transaction dated Tuesday, June 21st. The shares were acquired at an average cost of $10.84 per share, for a total transaction of $603,083.40. Following the completion of the purchase, the director now owns 209,188 shares in the company, valued at $2,267,597.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Venture Associates L. Index III sold 1,000,000 shares of the stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $10.00, for a total value of $10,000,000.00. The disclosure for this sale can be found here.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.